Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 786
Filtrar
1.
Vaccine ; 42(18): 3851-3856, 2024 Jul 11.
Artigo em Inglês | MEDLINE | ID: mdl-38749822

RESUMO

BACKGROUND: Case-control studies involving test-negative (TN) and syndrome-negative (SN) controls are reliable for evaluating influenza and rotavirus vaccine effectiveness (VE) during a random vaccination process. However, there is no empirical evidence regarding the impact in real-world mass vaccination campaigns against SARS-CoV-2 using TN and SN controls. OBJECTIVE: To compare in the same population the effectiveness of SARS-CoV-2 vaccination on COVID-19-related hospitalization rates across a cohort design, TN and SN designs. METHOD: We conducted an unmatched population-based cohort, TN and SN case-control designs linking data from four data sources (public primary healthcare system, hospitalization registers, epidemiological surveillance systems and the national immunization program) in a Chilean municipality (Rancagua) between March 1, 2021 and August 31, 2021. The outcome was COVID-19-related hospitalization. To ensure sufficient sample size in the unexposed group, completion of follow-up in the cohort design, and sufficient time between vaccination and hospitalization in the case-control design, VE was estimated comparing 8-week periods for each individual. RESULTS: Among the 191,505 individuals registered in the primary healthcare system of Rancagua in Chile on March 1, 2021; 116,453 met the cohort study's inclusion criteria. Of the 9,471 hospitalizations registered during the study period in the same place, 526 were COVID-19 cases, 108 were TN controls, and 1,628 were SN controls. For any vaccine product, the age- and sex-adjusted vaccine effectiveness comparing fully and nonvaccinated individuals was 67.2 (55.7-76.3) in the cohort design, whereas it was 67.8 (44.1-81.4) and 77.9 (70.2-83.8) in the TN and SN control designs, respectively. CONCLUSION: The VE of a COVID-19 vaccination program based on age and risk groups tended to differ across the three observational study designs. The SN case-control design may be an efficient option for evaluating COVID-19 VE in real-world settings.


Assuntos
Vacinas contra COVID-19 , COVID-19 , Hospitalização , Vacinação em Massa , SARS-CoV-2 , Eficácia de Vacinas , Humanos , COVID-19/prevenção & controle , COVID-19/epidemiologia , Chile/epidemiologia , Pessoa de Meia-Idade , Hospitalização/estatística & dados numéricos , Masculino , Feminino , Adulto , Idoso , Vacinas contra COVID-19/imunologia , Vacinas contra COVID-19/administração & dosagem , Estudos de Casos e Controles , Adolescente , SARS-CoV-2/imunologia , Vacinação em Massa/métodos , Vacinação em Massa/estatística & dados numéricos , Adulto Jovem , Criança , Pré-Escolar , Lactente , Estudos de Coortes , Programas de Imunização , Idoso de 80 Anos ou mais
2.
Hum Vaccin Immunother ; 20(1): 2348839, 2024 Dec 31.
Artigo em Inglês | MEDLINE | ID: mdl-38804600

RESUMO

In Singapore, population aging and rising life expectancy are increasing herpes zoster (HZ) burden, which may be reduced by vaccination. The present study modeled the public health impact of HZ vaccination in Singapore using ZOster ecoNomic Analysis (ZONA) model adapted with Singapore-specific key model inputs, where available. Base case analysis was conducted in adults ≥ 50 years of age (YOA), exploring three vaccination strategies (no vaccination, recombinant zoster vaccine [RZV], zoster vaccine live [ZVL]) under mass vaccination setting (30% coverage). Scenario and sensitivity analyses were performed. Out of 1.51 million adults in 2021 (base case population), 406,513 (27.0%) cases of HZ, 68,264 (4.5%) cases of post-herpetic neuralgia (PHN), and 54,949 (3.6%) cases of other complications were projected without vaccination. RZV was estimated to avoid 73,129 cases of HZ, 11,094 cases of PHN, and 9,205 cases of other complications over the subjects' remaining lifetime; ZVL would avoid 17,565 cases of HZ, 2,781 cases of PHN, and 1,834 cases of other complications. The number needed to vaccinate to prevent one case of HZ/PHN was lower for RZV (7/41) than ZVL (26/163). Among all five age-stratified cohorts (50-59/60-64/65-69/70-79/≥80 YOA), RZV (versus no vaccination/ZVL) avoided the largest number of cases in the youngest cohort, 50-59 YOA. Results were robust under scenario and sensitivity analyses. Mass vaccination with RZV is expected to greatly reduce the public health burden of HZ among Singapore individuals ≥ 50 YOA. Findings support value assessment and decision-making regarding public health vaccination strategies for HZ prevention in Singapore.


Risk of shingles (herpes zoster) increases with age, especially from 50 years. Shingles is a major public health concern in Singapore, given its rapidly aging population. Vaccination can prevent shingles and reduce its public health burden. Two shingles vaccines are available in Singapore: recombinant zoster vaccine (RZV) since 2021, zoster vaccine live (ZVL) since 2008. To understand the value of preventing shingles via vaccination, this study assessed the public health impact of shingles vaccination. Three vaccination strategies (no vaccination, vaccination with RZV, vaccination with ZVL) were compared in 1.51 million Singapore adults aged 50 years and above. Without vaccination, public health burden of shingles would be high; an estimated 406,513 (27.0%) would have shingles, 68,264 (4.5%) would have shingles-related long-term nerve pain, 54,949 (3.6%) would have other shingles-related complications, and 17,762 (1.2%) would be hospitalized due to shingles. Shingles vaccination could reduce this public health burden: RZV avoided 73,129 cases of shingles, 11,094 cases of shingles-related long-term nerve pain, 9,205 cases of other shingles-related complications, and 2,827 hospitalizations due to shingles, which was 4­6 times that avoided with ZVL (shingles: 17,565; shingles-related long-term nerve pain: 2,781; other shingles-related complications: 1,834; hospitalizations due to shingles: 484). Shingles vaccination for adults aged 50 years and above, especially early vaccination from 50­59 years, could reduce its public health burden more than vaccination at later ages and contribute toward healthy aging, preventive care, and the Healthier SG initiative. Results support local public health value assessments and decision-making for shingles prevention.


Assuntos
Vacina contra Herpes Zoster , Herpes Zoster , Saúde Pública , Humanos , Singapura/epidemiologia , Herpes Zoster/prevenção & controle , Herpes Zoster/epidemiologia , Vacina contra Herpes Zoster/administração & dosagem , Vacina contra Herpes Zoster/imunologia , Idoso , Pessoa de Meia-Idade , Masculino , Feminino , Idoso de 80 Anos ou mais , Neuralgia Pós-Herpética/prevenção & controle , Neuralgia Pós-Herpética/epidemiologia , Vacinação/estatística & dados numéricos , Vacinação em Massa/estatística & dados numéricos
3.
MMWR Morb Mortal Wkly Rep ; 73(19): 424-429, 2024 May 16.
Artigo em Inglês | MEDLINE | ID: mdl-38753539

RESUMO

Measles, a highly contagious respiratory virus with the potential to cause severe complications, hospitalization, and death, was declared eliminated from the United States in 2000; however, with ongoing global transmission, infections in the United States still occur. On March 7, 2024, the Chicago Department of Public Health (CDPH) confirmed a case of measles in a male aged 1 year residing in a temporary shelter for migrants in Chicago. Given the congregate nature of the setting, high transmissibility of measles, and low measles vaccination coverage among shelter residents, measles virus had the potential to spread rapidly among approximately 2,100 presumed exposed shelter residents. CDPH immediately instituted outbreak investigation and response activities in collaboration with state and local health departments, health care facilities, city agencies, and shelters. On March 8, CDPH implemented active case-finding and coordinated a mass vaccination campaign at the affected shelter (shelter A), including vaccinating 882 residents and verifying previous vaccination for 784 residents over 3 days. These activities resulted in 93% measles vaccination coverage (defined as receipt of ≥1 recorded measles vaccine dose) by March 11. By May 13, a total of 57 confirmed measles cases associated with residing in or having contact with persons from shelter A had been reported. Most cases (41; 72%) were among persons who did not have documentation of measles vaccination and were considered unvaccinated. In addition, 16 cases of measles occurred among persons who had received ≥1 measles vaccine dose ≥21 days before first known exposure. This outbreak underscores the need to ensure high vaccination coverage among communities residing in congregate settings.


Assuntos
Surtos de Doenças , Vacina contra Sarampo , Sarampo , Migrantes , Humanos , Sarampo/epidemiologia , Sarampo/prevenção & controle , Chicago/epidemiologia , Masculino , Lactente , Adulto , Adulto Jovem , Pré-Escolar , Adolescente , Criança , Vacina contra Sarampo/administração & dosagem , Migrantes/estatística & dados numéricos , Feminino , Pessoa de Meia-Idade , Vacinação em Massa/estatística & dados numéricos
5.
Artigo em Inglês | MEDLINE | ID: mdl-38673402

RESUMO

In the early phases of the COVID-19 pandemic, vaccine accessibility was limited, impacting large metropolitan areas such as Los Angeles County, which has over 10 million residents but only nine initial vaccination sites, which resulted in people experiencing long travel times to get vaccinated. We developed a mixed-integer linear model to optimize site selection, considering equitable access for vulnerable populations. Analyzing 277 zip codes between December 2020 and May 2021, our model incorporated factors such as car ownership, ethnic group disease vulnerability, and the Healthy Places Index, alongside travel times by car and public transit. Our optimized model significantly outperformed actual site allocations for all ethnic groups. We observed that White populations faced longer travel times, likely due to their residences being in more remote, less densely populated areas. Conversely, areas with higher Latino and Black populations, often closer to the city center, benefited from shorter travel times in our model. However, those without cars experienced greater disadvantages. While having many vaccination sites might improve access for those dependent on public transit, that advantage is diminished if people must search among many sites to find a location with available vaccines.


Assuntos
COVID-19 , Vacinação em Massa , Humanos , COVID-19/prevenção & controle , Los Angeles , Vacinação em Massa/estatística & dados numéricos , Acessibilidade aos Serviços de Saúde/estatística & dados numéricos , Vacinas contra COVID-19/administração & dosagem , SARS-CoV-2
6.
Public Health ; 231: 15-22, 2024 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-38593681

RESUMO

OBJECTIVE: This study comprehensively analyzed the temporal and spatial dynamics of COVID-19 cases and deaths within the obstetric population in Brazil, comparing the periods before and during mass COVID-19 vaccination. We explored the trends and geographical patterns of COVID-19 cases and maternal deaths over time. We also examined their correlation with the SARS-CoV-2 variant circulating and the social determinants of health. STUDY DESIGN: This is a nationwide population-based ecological study. METHODS: We obtained data on COVID-19 cases, deaths, socioeconomic status, and vulnerability information for Brazil's 5570 municipalities for both the pre-COVID-19 vaccination and COVID-19 vaccination periods. A Bayesian model was used to mitigate indicator fluctuations. The spatial correlation of maternal cases and fatalities with socioeconomic and vulnerability indicators was assessed using bivariate Moran. RESULTS: From March 2020 to June 2023, a total of 23,823 cases and 1991 maternal fatalities were recorded among pregnant and postpartum women. The temporal trends in maternal incidence and mortality rates fluctuated over the study period, largely influenced by widespread COVID-19 vaccination and the dominant SARS-CoV-2 variant. There was a significant reduction in maternal mortality due to COVID-19 following the introduction of vaccination. The geographical distribution of COVID-19 cases and maternal deaths exhibited marked heterogeneity in both periods, with distinct spatial clusters predominantly observed in the North, Northeast, and Central West regions. Municipalities with the highest Human Development Index reported the highest incidence rates, while those with the highest levels of social vulnerability exhibited elevated mortality and fatality rates. CONCLUSION: Despite the circulation of highly transmissible variants of concern, maternal mortality due to COVID-19 was significantly reduced following the mass vaccination. There was a heterogeneous distribution of cases and fatalities in both periods (before and during mass vaccination). Smaller municipalities and those grappling with social vulnerability issues experienced the highest rates of maternal mortality and fatalities.


Assuntos
Vacinas contra COVID-19 , COVID-19 , SARS-CoV-2 , Humanos , COVID-19/mortalidade , COVID-19/prevenção & controle , COVID-19/epidemiologia , Brasil/epidemiologia , Feminino , Vacinas contra COVID-19/administração & dosagem , Gravidez , Mortalidade Materna/tendências , Vacinação em Massa/estatística & dados numéricos , Teorema de Bayes , Complicações Infecciosas na Gravidez/prevenção & controle , Complicações Infecciosas na Gravidez/epidemiologia , Morte Materna/estatística & dados numéricos , Adulto , Fatores Socioeconômicos
7.
Trans R Soc Trop Med Hyg ; 117(5): 365-374, 2023 05 02.
Artigo em Inglês | MEDLINE | ID: mdl-36575997

RESUMO

BACKGROUND: Growing evidence supports the existence of a sex difference in immunity to tuberculosis (TB). This is most often to the detriment of males. This study aimed to assess the association between scar size from bacillus Calmette-Guérin (BCG) and mortality risk stratified by sex. METHODS: Kaplan-Meier survivor functions and Cox proportional hazard models were used to assess mortality risk by sex and scar size. Groups were further compared by clinical and epidemiological characteristics. RESULTS: Between 2003 and 2019, 2944 eligible patients were identified, of whom 1003 were included in the final analysis. Males with BCG scars, particularly large scars, were less likely to die within 1 y of diagnosis than males with no scar (adjusted hazard ratio 0.36 [95% confidence interval 0.15 to 0.88]). In contrast, females with small scars trended towards higher mortality than females with no scars or females with large scars. CONCLUSIONS: BCG protects against death in male but not female patients with TB. More research is needed to determine the mechanisms underpinning these sex differences and whether they are generalizable beyond this setting.


Assuntos
Vacina BCG , Tuberculose Pulmonar , Feminino , Humanos , Masculino , Vacina BCG/administração & dosagem , Cicatriz , Guiné-Bissau/epidemiologia , Modelos de Riscos Proporcionais , Tuberculose Pulmonar/epidemiologia , Tuberculose Pulmonar/prevenção & controle , Fatores Sexuais , Vacinação em Massa/estatística & dados numéricos
12.
Nat Hum Behav ; 6(2): 193-206, 2022 02.
Artigo em Inglês | MEDLINE | ID: mdl-35210582

RESUMO

The greatest hope for a return to normalcy following the COVID-19 pandemic is worldwide vaccination. Yet, a relaxation of social distancing that allows increased transmissibility, coupled with selection pressure due to vaccination, will probably lead to the emergence of vaccine resistance. We analyse the evolutionary dynamics of COVID-19 in the presence of dynamic contact reduction and in response to vaccination. We use infection and vaccination data from six different countries. We show that under slow vaccination, resistance is very likely to appear even if social distancing is maintained. Under fast vaccination, the emergence of mutants can be prevented if social distancing is maintained during vaccination. We analyse multiple human factors that affect the evolutionary potential of the virus, including the extent of dynamic social distancing, vaccination campaigns, vaccine design, boosters and vaccine hesitancy. We provide guidelines for policies that aim to minimize the probability of emergence of vaccine-resistant variants.


Assuntos
Vacinas contra COVID-19 , Farmacorresistência Viral , Imunogenicidade da Vacina , Vacinação em Massa , Distanciamento Físico , SARS-CoV-2 , COVID-19 , Vacinas contra COVID-19/imunologia , Vacinas contra COVID-19/farmacologia , Controle de Doenças Transmissíveis/organização & administração , Farmacorresistência Viral/efeitos dos fármacos , Farmacorresistência Viral/imunologia , Modelos Epidemiológicos , Humanos , Vacinação em Massa/métodos , Vacinação em Massa/estatística & dados numéricos , Formulação de Políticas , Probabilidade , SARS-CoV-2/efeitos dos fármacos , SARS-CoV-2/fisiologia , Processos Estocásticos , Hesitação Vacinal , Eficácia de Vacinas
13.
PLoS Comput Biol ; 18(2): e1009872, 2022 02.
Artigo em Inglês | MEDLINE | ID: mdl-35213541

RESUMO

COVID-19 vaccines have been approved for children of age five and older in many countries. However, there is an ongoing debate as to whether children should be vaccinated and at what priority. In this work, we use mathematical modeling and optimization to study how vaccine allocations to different age groups effect epidemic outcomes. In particular, we consider the effect of extending vaccination campaigns to include the vaccination of children. When vaccine availability is limited, we consider Pareto-optimal allocations with respect to competing measures of the number of infections and mortality and systematically study the trade-offs among them. In the scenarios considered, when some weight is given to the number of infections, we find that it is optimal to allocate vaccines to adolescents in the age group 10-19, even when they are assumed to be less susceptible than adults. We further find that age group 0-9 is included in the optimal allocation for sufficiently high values of the basic reproduction number.


Assuntos
Vacinas contra COVID-19 , COVID-19 , Alocação de Recursos para a Atenção à Saúde/estatística & dados numéricos , Vacinação em Massa , Modelos Estatísticos , Adolescente , Adulto , COVID-19/epidemiologia , COVID-19/prevenção & controle , Criança , Pré-Escolar , Humanos , Lactente , Recém-Nascido , Vacinação em Massa/métodos , Vacinação em Massa/estatística & dados numéricos , Adulto Jovem
14.
Sci Rep ; 12(1): 2055, 2022 02 08.
Artigo em Inglês | MEDLINE | ID: mdl-35136120

RESUMO

Understanding factors driving vaccine hesitancy is crucial to vaccination success. We surveyed adults (N = 2510) from February to March 2021 across five sites (Australia = 502, Germany = 516, Hong Kong = 445, UK = 512, USA = 535) using a cross-sectional design and stratified quota sampling for age, sex, and education. We assessed willingness to take a vaccine and a comprehensive set of putative predictors. Predictive power was analysed with a machine learning algorithm. Only 57.4% of the participants indicated that they would definitely or probably get vaccinated. A parsimonious machine learning model could identify vaccine hesitancy with high accuracy (i.e. 82% sensitivity and 79-82% specificity) using 12 variables only. The most relevant predictors were vaccination conspiracy beliefs, various paranoid concerns related to the pandemic, a general conspiracy mentality, COVID anxiety, high perceived risk of infection, low perceived social rank, lower age, lower income, and higher population density. Campaigns seeking to increase vaccine uptake need to take mistrust as the main driver of vaccine hesitancy into account.


Assuntos
Vacinas contra COVID-19/uso terapêutico , Vacinação em Massa/estatística & dados numéricos , Hesitação Vacinal/psicologia , Hesitação Vacinal/estatística & dados numéricos , Adulto , Austrália , COVID-19/prevenção & controle , Estudos Transversais , Países Desenvolvidos , Feminino , Alemanha , Hong Kong , Humanos , Programas de Imunização/métodos , Aprendizado de Máquina , Masculino , Pessoa de Meia-Idade , SARS-CoV-2/imunologia , Reino Unido , Estados Unidos
16.
PLoS One ; 17(2): e0263610, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-35180249

RESUMO

Vaccination has emerged as the most cost-effective public health strategy for maintaining population health, with various social and economic benefits. These vaccines, however, cannot be effective without widespread acceptance. The present study examines the effect of media attention on COVID-19 vaccine hesitancy by incorporating fear of COVID-19 as a mediator, whereas trust in leadership served as a moderator. An analytical cross-sectional study is performed among rural folks in the Wassa Amenfi Central of Ghana. Using a questionnaire survey, we were able to collect 3079 valid responses. The Smart PLS was used to estimate the relationship among the variables. The results revealed that media attention had a significant influence on vaccine hesitancy. Furthermore, the results showed that fear of COVID-19 played a significant mediating role in the relationship between media and vaccine hesitancy. However, trust in leadership had an insignificant moderating relationship on the fear of COVID-19 and vaccine hesitancy. The study suggests that the health management team can reduce vaccine hesitancy if they focus on lessening the negative impact of media and other antecedents like fear on trust in leadership.


Assuntos
Vacinas contra COVID-19/administração & dosagem , COVID-19/prevenção & controle , Meios de Comunicação/estatística & dados numéricos , Vacinação em Massa/psicologia , Hesitação Vacinal , Adolescente , Adulto , Idoso , Movimento contra Vacinação/psicologia , Movimento contra Vacinação/estatística & dados numéricos , COVID-19/epidemiologia , Estudos Transversais , Medo , Feminino , Gana/epidemiologia , Humanos , Liderança , Masculino , Vacinação em Massa/estatística & dados numéricos , Pessoa de Meia-Idade , População Rural/estatística & dados numéricos , Inquéritos e Questionários/estatística & dados numéricos , Confiança , Adulto Jovem
17.
JAMA Netw Open ; 5(2): e2147042, 2022 02 01.
Artigo em Inglês | MEDLINE | ID: mdl-35147688

RESUMO

Importance: Given limited COVID-19 vaccine availability early in the pandemic, optimizing immunization strategies was of paramount importance. Ring vaccination has been used successfully to control transmission of other airborne respiratory viruses. Objective: To assess the association of a ring vaccination intervention on COVID-19 spread in the initial epicenter of SARS-CoV-2 Alpha variant transmission in Montreal, Canada. Design, Setting, and Participants: This cohort study compared COVID-19 daily disease risk in 3 population-based groups of neighborhoods in Montreal, Canada, defined by their intervention-specific vaccine coverage at the neighborhood level: the primary intervention group (500 or more vaccinated persons per 10 000 persons), secondary intervention group (95 to 499), and control group (0 to 50). The groups were compared within each of 3 time periods: before intervention (December 1, 2020, to March 16, 2021), during and immediately after intervention (March 17 to April 17, 2021), and 3 weeks after the intervention midpoint (April 18 to July 18, 2021). Data were analyzed between June 2021 and November 2021. Exposures: Vaccination targeted parents and teachers of children attending the 32 schools and 48 childcare centers in 2 adjacent neighborhoods with highest local transmission (case counts) of Alpha variant shortly after its introduction. Participants were invited to receive 1 dose of mRNA vaccine between March 22 and April 9, 2021 (before vaccine was available to these age groups). Main Outcomes and Measures: COVID-19 risk in 3 groups of neighborhoods based on intervention-specific vaccine coverage. Results: A total of 11 794 residents were immunized, with a mean (SD) age of 43 (8) years (range, 16-93 years); 5766 participants (48.9%) lived in a targeted neighborhood, and 9784 (83.0%) were parents. COVID-19 risk in the primary intervention group was significantly higher than in the control group before (unadjusted risk ratio [RR], 1.58; 95% CI 1.52-1.65) and during (RR, 1.63; 95% CI, 1.52-1.76) intervention, and reached a level similar to the other groups in the weeks following the intervention (RR, 1.03; 95% CI, 0.94-1.12). A similar trend was observed when restricting to SARS-CoV-2 variants and persons aged 30 to 59 years (before: RR, 1.72; 95% CI, 1.63-1.83 vs after: RR, 1.01; 95% CI, 0.88-1.17). Conclusions and Relevance: Our findings show that ring vaccination was associated with a reduction in COVID-19 risk in areas with high local transmission of Alpha variant shortly after its introduction. Ring vaccination may be considered as an adjunct to mass immunization to control transmission in specific areas, based on local epidemiology.


Assuntos
Tratamento Farmacológico da COVID-19 , COVID-19/transmissão , Medição de Risco/métodos , Vacinação/normas , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , COVID-19/epidemiologia , Criança , Estudos de Coortes , Feminino , Humanos , Masculino , Vacinação em Massa/métodos , Vacinação em Massa/normas , Vacinação em Massa/estatística & dados numéricos , Pessoa de Meia-Idade , Razão de Chances , Vigilância da População/métodos , Quebeque/epidemiologia , Medição de Risco/estatística & dados numéricos , SARS-CoV-2/efeitos dos fármacos , SARS-CoV-2/patogenicidade , Vacinação/métodos , Vacinação/estatística & dados numéricos
18.
Viruses ; 14(1)2022 01 14.
Artigo em Inglês | MEDLINE | ID: mdl-35062358

RESUMO

Oral rabies vaccines (ORVs) have been in use to successfully control rabies in wildlife since 1978 across Europe and the USA. This review focuses on the potential and need for the use of ORVs in free-roaming dogs to control dog-transmitted rabies in India. Iterative work to improve ORVs over the past four decades has resulted in vaccines that have high safety profiles whilst generating a consistent protective immune response to the rabies virus. The available evidence for safety and efficacy of modern ORVs in dogs and the broad and outspoken support from prominent global public health institutions for their use provides confidence to national authorities considering their use in rabies-endemic regions. India is estimated to have the largest rabies burden of any country and, whilst considerable progress has been made to increase access to human rabies prophylaxis, examples of high-output mass dog vaccination campaigns to eliminate the virus at the source remain limited. Efficiently accessing a large proportion of the dog population through parenteral methods is a considerable challenge due to the large, evasive stray dog population in many settings. Existing parenteral approaches require large skilled dog-catching teams to reach these dogs, which present financial, operational and logistical limitations to achieve 70% dog vaccination coverage in urban settings in a short duration. ORV presents the potential to accelerate the development of approaches to eliminate rabies across large areas of the South Asia region. Here we review the use of ORVs in wildlife and dogs, with specific consideration of the India setting. We also present the results of a risk analysis for a hypothetical campaign using ORV for the vaccination of dogs in an Indian state.


Assuntos
Doenças do Cão/prevenção & controle , Vacinação em Massa/veterinária , Vacina Antirrábica/administração & dosagem , Raiva/prevenção & controle , Raiva/veterinária , Vacinação/veterinária , Administração Oral , Animais , Animais Selvagens/imunologia , Anticorpos Antivirais/sangue , Doenças do Cão/epidemiologia , Doenças do Cão/virologia , Cães , Índia/epidemiologia , Vacinação em Massa/normas , Vacinação em Massa/estatística & dados numéricos , Raiva/epidemiologia , Raiva/imunologia , Vacina Antirrábica/imunologia , Vírus da Raiva/imunologia , Vacinação/estatística & dados numéricos
20.
J Korean Med Sci ; 37(3): e23, 2022 Jan 17.
Artigo em Inglês | MEDLINE | ID: mdl-35040298

RESUMO

BACKGROUND: The military was one of the first groups in Korea to complete mass vaccination against the coronavirus disease 2019 (COVID-19) due to their high vulnerability to COVID-19. To confirm the effect of mass vaccination, this study analyzed the patterns of confirmed cases within Korean military units. METHODS: From August 1 to September 15, 2021, all epidemiological data regarding confirmed COVID-19 cases in military units were reviewed. The number of confirmed cases in the units that were believed to have achieved herd immunity (i.e., ≥ 70% vaccination) was compared with the number of cases in the units that were not believed to have reached herd immunity (< 70% vaccination). Additionally, trends in the incidence rates of COVID-19 in the military and the entire Korean population were compared. RESULTS: By August 2021, 85.60% of military personnel were fully vaccinated. During the study period, a total of 174 COVID-19 cases were confirmed in the 39 units. More local transmission (herd immunity group vs. non-herd immunity group [%], 1 [0.91] vs. 39 [60.94]) and hospitalizations (12 [11.01] vs. 13 [27.08]) occurred in the units that were not believed to have achieved herd immunity. The percentage of fully vaccinated individuals among the confirmed COVID-19 cases increased over time, possibly due to the prevalence of the delta variant. Nevertheless, the incidence rate remained lower in military units than in the general Korean population. CONCLUSION: After completing mass vaccination, the incidence rates of COVID-19 infection in the military were lower than those in the national population. New cluster infections did not occur in vaccinated units, thereby suggesting that herd immunity has been achieved in these military units. Further research is needed to determine the extent to which levels of non-pharmacological intervention can be reduced in the future.


Assuntos
COVID-19/epidemiologia , Vacinação em Massa/estatística & dados numéricos , Militares/estatística & dados numéricos , COVID-19/prevenção & controle , Vacinas contra COVID-19 , Hospitalização/estatística & dados numéricos , Humanos , Imunidade Coletiva/imunologia , Incidência , República da Coreia/epidemiologia , SARS-CoV-2/imunologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...